Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Payables (2016 - 2025)

Traws Pharma's Payables history spans 14 years, with the latest figure at $5.7 million for Q4 2025.

  • Quarterly results put Payables at $5.7 million for Q4 2025, down 30.94% from a year ago — trailing twelve months through Dec 2025 was $5.7 million (down 30.94% YoY), and the annual figure for FY2025 was $5.7 million, down 30.94%.
  • Payables for Q4 2025 was $5.7 million at Traws Pharma, up from $5.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $8.2 million in Q4 2024 to a low of $2.8 million in Q4 2021.
  • The 5-year median for Payables is $5.0 million (2023), against an average of $5.0 million.
  • The sharpest move saw Payables tumbled 42.95% in 2021, then soared 68.86% in 2023.
  • Year by year, Payables stood at $2.8 million in 2021, then skyrocketed by 40.01% to $3.9 million in 2022, then soared by 45.57% to $5.6 million in 2023, then surged by 45.68% to $8.2 million in 2024, then plummeted by 30.94% to $5.7 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $5.7 million, $5.1 million, and $4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.